Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis […]readmore
Tags : Hill-Rom
Shots: Baxter in talks to acquire Hill-Rom for ~$10B with $150/ share representing a premium of 13% to the stock’s closing price of $132.90. The acquisition is expected to be […]readmore